Collutorium: 120 ml bottles. Spray: 30 ml container, with a sprayer-metering valve.
Packaging containing 30 and 60 capsules.
BLOKIUM FLEX – coated tablets: containers having l5 and 30 coated tablets.
BLOKIUM FLEX –IM injection: containers having 3 ampoules with diluent and 3 vials with lyophilized.
BLOKIUM FLEX –IM injection: containers having 6 ampoules with diluent y 6 vials with lyophilized.
Packages containing l0 and 20 lozenges.
Corticosteroid of rapid and prolonged action.
Osteoarticular pathologies requiring systemic corticotherapy or local infiltration (tendinitis, tenosynovitis, bursitis, cervicalgias, backalgias, lumbosciatalgias). Allergic or inflammatory pathologies of the upper and lower airways. Inflammatory or allergic dermatitis.
Dosage and Mode of Administration
Systemic Treatment: It is generally initiated with doses of 1 to 2 mL repeated as required, in the form of a deep intramuscular injection. The dose and frequency of administration will depend on the severity of the disorder and the clinical response. In the management of pathologies such as lupus erythematosus or asthma, 2 mL may be initially administered. In the case of dermopathies, a 1-mL intramuscular injection repeated according to the therapeutic response is generally effective. As regards bronchial asthma, hay fever, bronchitis, and allergic rhinitis, an optimal result is obtained with 1 to 2 mL. In the treatment of acute or chronic bursitis, favorable results are obtained with intramuscular injections of 1 to 2 mL of CRONO CORTICAS.
Local Treatment: In subdeltoid, subacromial, olecranon, and pre-patellar bursitis, an intrabursal injection of 1 to 2 mL of CRONO CORTICAS relieves the painful symptom and rapidly reestablishes movement. Chronic bursitis may be treated with reduced doses after the acute event is controlled. In the presence of acute tenosynovitis, tendinitis, and peritendinitis, a single administration allows to reach favorable results. In rheumatoid arthritis and osteoarthritis, intraarticular administration of 0.5 to 2 mL of CRONO CORTICAS, according to the size of the joint affected, achieves pain and rigidity relief in 2-4 hours, the improvement lasting 4 weeks or longer in most cases.
The intraarticular use of CRONO CORTICAS may be scheduled as follows: * large joints (knee, hip, shoulder): 1 to 2 mL; * medium joints (elbow, wrist, ankle): 0.5 to 1 mL; * small joints (foot, hand): 0.25 to 0.5 mL. Skin conditions may be adequately controlled with intramuscular administration.
If intralesional treatment is chosen, an intradermal dose of 0,2 mL/cm2 of CRONO CORTICAS uniformly injected with a tuberculine syringe with fine needle is suggested. The amount of CRONO CORTICAS injected per week in all sites should not exceed 1 mL. CRONO CORTICAS may also be used in those foot conditions unresponsive to corticosteroids. Hard corn bursitis (heloma durum) may be treated with two successive injections of 0.25 mL. In the case of rigid hallux and acute gouty arthritis, relief is rapidly obtained. A tuberculine syringe with fine needle is adequate for most injections applied to the feet.
The doses recommended may be summarized as follows: soft corn bursitis: 0.25 to 0.50 mL; calcaneal spur: 0.5 mL; rigid hallux: 0.5 mL; synovial cyst: 0.25 to 0.50 mL, tenosynovitis: 0.5 mL; periostitis: 0.50 mL; acute gouty arthritis 0.50 to 1 mL. If necessary, use a local anesthetic, which may be mixed with CRONO CORTICAS in the syringe (not in the vial). Preferred anesthetics are 1% - 2% procaine or lidocaine hydrochloride using preparations not containing parabens, phenol, etc. The CRONO CORTICAS dose required is extracted from the vial with the syringe and then the anesthetic is added, slightly stirring the syringe.
Note: If the drug is to be discontinued following prolonged treatment, the dose should be gradually diminished.
Active tuberculosis (unless anti-TB chemotherapeutic agents are used). Systemic mycoses. Viral disease. Serious heart failure. Blood hypertension. Gastroduodenal ulcer. Acute psychosis. Osteoporosis. Hypersensitivity to the active ingredient. Epilepsy. Glaucoma. Not to be administered intramuscularly to patients with idiopathic thrombocytopenic purpura.
Packages containing one 2-mL vial + 1 disposable syringe with needle.